<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Somatic mtDNA mutations have been reported in some human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, but their spectrum in different <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and their role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development remain incompletely understood </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we describe the breadth of somatic and inherited mutations across the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> genome by sequence analyses of paired <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> tissue samples from 226 individuals with five types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> using whole-genome data generated by The <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Genome Atlas Research Network </plain></SENT>
<SENT sid="2" pm="."><plain>The frequencies of deleterious <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> found in mtDNA varied across <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types, ranging from 13% of <z:hpo ids='HP_0100843'>glioblastomas</z:hpo> to 63% of <z:mp ids='MP_0009315'>rectal adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with inherited mtDNA variants, somatic mtDNA mutations were enriched for nonsynonymous vs. synonymous changes (93 vs. 15; P &lt; 2.2E-16) and were predicted to functionally impact the encoded protein </plain></SENT>
<SENT sid="4" pm="."><plain>Somatic missense mutations in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were distributed uniformly among the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> protein genes, but 65% of somatic truncating mutations occurred in <z:chebi fb="0" ids="16908">NADH</z:chebi> dehydrogenase 5 </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of staging data in colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> revealed that the frequency of damaging <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> mutations is the same in stages I and IV <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In summary, these data suggest that damaging somatic mtDNA mutations occur frequently (13-63%) in these five <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types and likely confer a selective advantage in <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
</text></document>